Study #2020-1241
Strategic Alliance: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination with Fulvestrant in ER+ and/or PR+ Cancers with PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
MD Anderson Study Status
Not Accepting
Treatment Agent
Copanlisib, fulvestrant
Description
The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring alterations that activate the Phosphatidylinositol-3 kinase (PI3K) pathway.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endometrial Cancer, Ovarian Cancer
Study phase:
Phase II
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-317-6206
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.